 GlaxoSmithKline plc NYSE: GSK has agreed to sell 32 million shares in Innoviva Inc NASDAQ: INVA back to the royalty management company, raising 392 million, at a 3 discount or 12.25 per share. Innoviva, a royalty management company that collaborates with GSK on respiratory treatments, including Breo Ellipta, Anoro Ellipta, and Trelegy Ellipta, has counted GSK among its investors for years. 